CommercialMcKesson Invests $2.5B to Acquire Majority Stake in Florida-Based...

McKesson Invests $2.5B to Acquire Majority Stake in Florida-Based Community Oncology

-

McKesson has planned to enhance its oncology platform with a significant investment of approximately $2.5 billion into the business and administrative services subsidiary of a community oncology clinic group. The deal involves McKesson acquiring a 70% stake in Core Ventures, a company recently formed by the Florida Cancer Specialists & Research Institute (FCS).

FCS is a large cancer care organization headquartered in Fort Myers, with over 250 oncologists, 280 cancer specialists, and nearly 100 branches across Florida. Despite the acquisition, FCS will remain a separate entity under the ownership of its physicians, who collectively retain a minority interest in Core Ventures, which is now majority-owned by McKesson.
Once the transaction meets certain closing conditions and receives regulatory approvals, Core Ventures will be integrated into McKesson’s oncology platform. McKesson CEO Brian Tyler stated that this expansion will improve the quality of treatment by offering better solutions and experiences for patients over time, as well as reducing healthcare costs. He further noted that the patient-centric development strategy pursued by FCS and Core Ventures aligns with McKesson’s vision of fostering clinical growth and extending quality cancer care to more people.
The acquisition will also connect FCS to McKesson’s U.S. Oncology Network, which consists of over 60 care delivery locations and 2,500 associated physicians. This partnership will provide FCS with the benefits of McKesson’s oncology products and services. FCS CEO Nathan Walcker expressed his enthusiasm about the collaboration, highlighting that both organizations aim to build a strong foundation in the fight against cancer, ultimately improving outcomes for oncology patients.

This acquisition is part of a broader trend in which community-based oncology practices have become attractive targets for healthcare, pharmaceutical, and supply distributors. Recent reports from Bloomberg have confirmed that other industry giants, including Cencora and Cardinal Health, have also shown interest in FCS. Once the deal is finalized, FCS’s physician owners will remain significantly invested in the institute; however, they will not control the decisions made by the institute.

Life Sciences Voice Logo mobile
+ posts

Latest news

Top 10 Pharma News Websites You Should Follow in 2026

Executive Summary In 2026, pharma and biotech are evolving at unprecedented speed. AI-driven drug discovery, digital transformation, personalized medicine, and...

How Are Life Sciences Companies Raising Capital in 2026?

Executive Summary In 2026, raising capital in life sciences is no longer about access—it is about proof. The traditional reliance...

Kailera Details Nasdaq IPO Plans to Raise Up to $528.5 Million for Obesity Drug Development

Kailera Therapeutics has provided additional details regarding its planned initial public offering, aiming to raise up to $528.5 million...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you